Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALPG | P10696 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507854 | 0.80 | ALDH1A1 (0.53) | ALDH1A1LMNASMN1; SMN2HPGDALPG | |
| SCHEMBL1443906 | 0.75 | SLC6A4 (0.39) | ALDH1A1SMN1; SMN2NPSR1MEN1KMT2A | |
| SCHEMBL1443940 | 0.75 | PTGS2 (0.39) | ALDH1A1SMN1; SMN2NPSR1MEN1KMT2A | |
| SCHEMBL10708532 | 0.73 | NFE2L2 (0.42) | ALDH1A1LMNASMN1; SMN2HPGDMEN1 | |
| SCHEMBL29031381 | 0.73 | ALDH1A1 (0.46) | ALDH1A1LMNASMN1; SMN2HPGDALPG | |
| SCHEMBL533630 | 0.70 | PTGS2 (0.50) | ALDH1A1NPSR1PTGS2PTGS1SLC6A4 | |
| SCHEMBL16142244 | 0.70 | ALDH1A1 (0.40) | ALDH1A1LMNASMN1; SMN2HPGDALPG | |
| SCHEMBL13006374 | 0.70 | CA12 (0.56) | ALDH1A1SMN1; SMN2PTGS2PTGS1SLC6A4 | |
| SCHEMBL1443967 | 0.69 | HDAC4 (0.41) | ALDH1A1NPSR1GAAPTGS2PTGS1 | |
| SCHEMBL27782003 | 0.67 | TRPA1 (0.50) | ALDH1A1NPSR1MEN1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011034860-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20100056637-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090036538-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1968563-A2 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | Icagen, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1158971-B1 | GARDOS CHANNEL ANTAGONISTS | ICAGEN INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | ICAGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007075849-A2 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1158971-A4 | GARDOS CHANNEL ANTAGONISTS | ICAGEN INC (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1158971-A1 | GARDOS CHANNEL ANTAGONISTS | Icagen, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6288122-B1 | A TRIPHENYL ACETAMIDE | ICAGEN, INC. | 2001-09-11 | — | — | US | disclosed |
| WO-2000050026-A1 | GARDOS CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | KCNH3, KCNH2, KCNJ2 | ALDH1A1 3554/4885LMNA 2633/4885SMN1; SMN2 430/4885 |
| US-20090036538-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | KCNH3, KCNH2, KCNJ2 | ALDH1A1 3554/4885LMNA 2633/4885SMN1; SMN2 430/4885 |
| US-20100056637-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | LTC4S, LTB4R2, CYSLTR2 | ALDH1A1 1201/4885LMNA 2539/4885SMN1; SMN2 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.